Literature DB >> 10664370

The pathogenesis of tumour associated epilepsy.

A Beaumont1, I R Whittle.   

Abstract

Tumour associated epilepsy (TAE) is a poorly understood manifestation of many gliomas, meningiomas and metastatic brain tumours that has important clinical and social implications. Etiological mechanisms underlying tumour associated epilepsy include theories invoking peritumoural amino acid disturbances, local metabolic imbalances, cerebral oedema, pH abnormalities, morphological changes in the neuropil, changes in neuronal and glial enzyme and protein expression and altered immunological activity. It has also been suggested that the pathology involves perturbations in distribution and function of the NMDA subclass of glutamate receptors. The often capricious response of the seizure disorder following removal of the causative neoplasms suggests multiple factors are involved. Further understanding about the pathogenesis of TAE will await the development and characterisation of suitable animal models that demonstrate the clinical manifestations and physiological changes comparable to those seen in human cerebral tumours. With such a model it is hoped that progress may one day be made in understanding and subsequently treating this debilitating clinical problem.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10664370     DOI: 10.1007/s007010050001

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  45 in total

Review 1.  A-to-I RNA editing and human disease.

Authors:  Stefan Maas; Yukio Kawahara; Kristen M Tamburro; Kazuko Nishikura
Journal:  RNA Biol       Date:  2006-01-12       Impact factor: 4.652

Review 2.  Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?

Authors:  B J Schaller; M Modo; M Buchfelder
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

Review 3.  Tumor-related epilepsy: epidemiology, pathogenesis and management.

Authors:  Dillon Y Chen; Clark C Chen; John R Crawford; Sonya G Wang
Journal:  J Neurooncol       Date:  2018-05-24       Impact factor: 4.130

Review 4.  Treatment of epileptic seizures in brain tumors: a critical review.

Authors:  R Bauer; M Ortler; M Seiz-Rosenhagen; R Maier; J V Anton; I Unterberger
Journal:  Neurosurg Rev       Date:  2014-04-24       Impact factor: 3.042

Review 5.  Glutamate transporters in the biology of malignant gliomas.

Authors:  Stephanie M Robert; Harald Sontheimer
Journal:  Cell Mol Life Sci       Date:  2013-11-27       Impact factor: 9.261

Review 6.  Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments.

Authors:  Roberta Rudà; Lorenzo Bello; Hugues Duffau; Riccardo Soffietti
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

7.  Cortical hemosiderin is associated with seizures in patients with newly diagnosed malignant brain tumors.

Authors:  Ulrich Roelcke; Larissa Boxheimer; Ali Reza Fathi; Lucia Schwyzer; Marcos Ortega; Jatta Berberat; Luca Remonda
Journal:  J Neurooncol       Date:  2013-09-18       Impact factor: 4.130

8.  Epilepsy in cerebral glioma: timing of appearance and histological correlations.

Authors:  Anna Rosati; Alessia Tomassini; Bianca Pollo; Claudia Ambrosi; Andreas Schwarz; Alessandro Padovani; Bruno Bonetti
Journal:  J Neurooncol       Date:  2009-01-29       Impact factor: 4.130

Review 9.  Central nervous system toxicity from cancer treatment.

Authors:  Terri Armstrong; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

10.  Epilepsy is related to theta band brain connectivity and network topology in brain tumor patients.

Authors:  Linda Douw; Edwin van Dellen; Marjolein de Groot; Jan J Heimans; Martin Klein; Cornelis J Stam; Jaap C Reijneveld
Journal:  BMC Neurosci       Date:  2010-08-23       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.